Brief: FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
21/11/2024 12:03
Nov 21 (Reuters) - Novocure Ltd NVCR.O :
* FDA APPROVES NOVOCURE’S INNOVATIVE HFE TRANSDUCER ARRAYS
FOR USE
WITH OPTUNE GIO® FOR GLIOBLASTOMA
* NOVOCURE LTD - TO CONVERT OPTUNE GIO USERS TO NEW HFE
ARRAYS BY
MID-2025
Source text: ID:nBw4MSz05a
Further company coverage: NVCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture